武田药品更新了其2024财年的管理指导和报告及核心预测。这些调整主要受产品动能和运营费用节约的推动，同时也反映了修订后的全年汇率假设。根据最新的预测，核心收入预计将小幅增长，而核心每股收益预计与之前持平或略微下降。此外，自由现金流的预期被上调至5500亿至6500亿日元。查看更多详情，请参考《2024财年财务预测修订公告（IFRS）》。

以上内容来自Benzinga Earnings专栏，原文如下：

FY2024 OutlookUpdating Full Year Management Guidance and Reported and Core Forecasts

Takeda has upgraded its FY2024 Management Guidance, primarily driven by product momentum and OPEX savings. In addition, and also reflecting revised foreign exchange assumptions for the year, Takeda has raised its FY2024 reported and Core forecasts from the previous forecast. For more details, see release: Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)

FY2024 Management Guidance Core Change at CER (Non-IFRS)
	FY2024 PREVIOUS MANAGEMENT GUIDANCE (October 2024)	FY2024 REVISED MANAGEMENT GUIDANCE (January 2025)
Core Revenue	Flat to slightly increasing	Low-single-digit % increase
Core Operating Profit	Mid-single-digit % decline	Low-single-digit % increase
Core EPS (Yen)	Approx 10% decline	Flat to slightly declining

FY2024 Reported and Core Forecasts
(Billion yen, except percentages and per share amounts)
	FY2024PREVIOUS FORECAST (October 2024)	FY2024 REVISED FORECAST (January 2025)
Revenue	4,480.0	4,590.0
Core Revenue (Non-IFRS)	4,480.0	4,590.0
Operating Profit	265.0	344.0
Core Operating Profit (Non-IFRS)	1,050.0	1,150.0
Net Profit	68.0	118.0
EPS (Yen)	43	75
Core EPS (Yen) (Non-IFRS)	456	507
Adjusted Free Cash Flow (Non-IFRS)	400.0-500.0	550.0-650.0
Annual Dividend per Share (Yen)	196	196